- Home
- ICCC vs RAND Comparison
ICCC vs RAND Comparison
Compare ICCC & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- RAND
- Stock Information
- Founded
- ICCC 1982
- RAND 1969
- Country
- ICCC United States
- RAND United States
- Employees
- ICCC N/A
- RAND N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- RAND Finance: Consumer Services
- Sector
- ICCC Health Care
- RAND Finance
- Exchange
- ICCC Nasdaq
- RAND Nasdaq
- Market Cap
- ICCC 28.7M
- RAND 47.5M
- IPO Year
- ICCC 1987
- RAND N/A
- Fundamental
- Price
- ICCC $3.55
- RAND $16.78
- Analyst Decision
- ICCC
- RAND
- Analyst Count
- ICCC 0
- RAND 0
- Target Price
- ICCC N/A
- RAND N/A
- AVG Volume (30 Days)
- ICCC 20.8K
- RAND 1.3K
- Earning Date
- ICCC 11-13-2024
- RAND 11-04-2024
- Dividend Yield
- ICCC N/A
- RAND 6.92%
- EPS Growth
- ICCC N/A
- RAND 72.67
- EPS
- ICCC N/A
- RAND 4.19
- Revenue
- ICCC $23,222,929.00
- RAND $7,874,601.00
- Revenue This Year
- ICCC N/A
- RAND N/A
- Revenue Next Year
- ICCC N/A
- RAND N/A
- P/E Ratio
- ICCC N/A
- RAND $3.91
- Revenue Growth
- ICCC 48.05
- RAND 13.24
- 52 Week Low
- ICCC $3.34
- RAND $12.50
- 52 Week High
- ICCC $5.59
- RAND $19.60
- Technical
- Relative Strength Index (RSI)
- ICCC 43.90
- RAND 48.97
- Support Level
- ICCC $3.51
- RAND $16.39
- Resistance Level
- ICCC $3.74
- RAND $17.26
- Average True Range (ATR)
- ICCC 0.17
- RAND 0.28
- MACD
- ICCC 0.00
- RAND 0.01
- Stochastic Oscillator
- ICCC 18.60
- RAND 44.25
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, diversified management company. The firm's investment objectives is to maximize the total return to the shareholders with current income combined with capital appreciation. Some of its portfolios include lumious, and GiveGab among others.